Impact of Sustained Virological Response for Gastroesophageal Varices in Hepatitis-C-Virus-Related Liver Cirrhosis.

direct-acting antivirals gastroesophageal varices hepatitis C virus interferon liver cirrhosis sustained virological response

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
30 Dec 2019
Historique:
received: 09 12 2019
accepted: 27 12 2019
entrez: 8 1 2020
pubmed: 8 1 2020
medline: 8 1 2020
Statut: epublish

Résumé

We aimed to clarify the relationship between sustained virological response (SVR) and gastroesophageal varices (GEVs) progression among hepatitis C virus (HCV)-related liver cirrhosis (LC) patients treated with interferon (IFN)-based therapies (

Identifiants

pubmed: 31905953
pii: jcm9010095
doi: 10.3390/jcm9010095
pmc: PMC7019884
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Gastroenterology. 2017 Nov;153(5):1273-1283.e1
pubmed: 28734831
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
Viruses. 2018 Oct 06;10(10):
pubmed: 30301201
J Hepatol. 2017 Apr;66(4):711-717
pubmed: 27965158
J Gastroenterol. 2014 Aug;49(8):1253-63
pubmed: 24065124
Gastroenterology. 2019 Jan;156(2):446-460.e2
pubmed: 30367836
Clin Infect Dis. 2020 Mar 3;70(6):1208-1214
pubmed: 31056696
Lancet. 2015 Mar 21;385(9973):1124-35
pubmed: 25687730
J Viral Hepat. 2019 Nov;26(11):1249-1256
pubmed: 31243849
Gastroenterology. 2016 Jul;151(1):130-139.e2
pubmed: 27039970
J Viral Hepat. 2017 Oct;24(10):823-831
pubmed: 28295923
Hepatology. 2010 Jun;51(6):2069-76
pubmed: 20196120
Hepatol Res. 2016 Sep;46(10):951-63
pubmed: 27481650
BMC Infect Dis. 2015 Jan 17;15:19
pubmed: 25596623
Lancet Gastroenterol Hepatol. 2017 Nov;2(11):832-836
pubmed: 28802815
J Infect. 2019 Dec;79(6):503-512
pubmed: 31629015
J Gastroenterol. 2020 Feb;55(2):205-216
pubmed: 31493238
Gastroenterology. 2019 Mar;156(4):997-1009.e5
pubmed: 30768988
Endocr Metab Immune Disord Drug Targets. 2020;20(1):104-111
pubmed: 31448717
J Hepatol. 2016 Oct;65(4):692-699
pubmed: 27242316
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
J Hepatol. 2016 Oct;65(1 Suppl):S95-S108
pubmed: 27641991
Gastroenterology. 2017 Oct;153(4):996-1005.e1
pubmed: 28642197
J Gastroenterol. 2016 Jul;51(7):629-50
pubmed: 27246107
Nutrients. 2017 Oct 18;9(10):
pubmed: 29057827
Aliment Pharmacol Ther. 2018 May;47(10):1409-1415
pubmed: 29569736
Hepatology. 2002 Nov;36(5 Suppl 1):S3-20
pubmed: 12407572
Gastroenterology. 2014 Jul;147(1):132-142.e4
pubmed: 24704719
J Hepatol. 2017 Mar;66(3):485-493
pubmed: 27780714
Cells. 2019 Apr 04;8(4):
pubmed: 30987413
Gut. 2018 Nov;67(11):2025-2034
pubmed: 29703790
Antivir Ther. 2018;23(2):129-138
pubmed: 28799522
Hepatol Int. 2015 Jan;9(1):67-75
pubmed: 25788381
World J Gastroenterol. 2017 Jul 14;23(26):4669-4674
pubmed: 28765688

Auteurs

Yukihisa Yuri (Y)

Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.

Hiroki Nishikawa (H)

Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.
Center for clinical research and education, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.

Hirayuki Enomoto (H)

Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.

Kazunori Yoh (K)

Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.

Yoshinori Iwata (Y)

Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.

Yoshiyuki Sakai (Y)

Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.

Kyohei Kishino (K)

Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.

Naoto Ikeda (N)

Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.

Tomoyuki Takashima (T)

Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.

Nobuhiro Aizawa (N)

Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.

Ryo Takata (R)

Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.

Kunihiro Hasegawa (K)

Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.

Noriko Ishii (N)

Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.

Takashi Nishimura (T)

Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.

Hiroko Iijima (H)

Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.

Shuhei Nishiguchi (S)

Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.

Classifications MeSH